« Return to News | R&D Trends

IMI creates platform to discover novel medicines

Monday, March 12, 2012 02:04 PM

In an effort to speed up the discovery of new medicines, the Innovative Medicines Initiative (IMI) has created the European Lead Factory, a Europe-wide public-private partnership that combines the Joint European Compound Collection, a comprehensive collection of candidate drug molecules, with an industry-like screening center.

The pharmaceutical companies involved in the future project have committed to contributing at least 300,000 chemical compounds from their otherwise safeguarded corporate chemical collections. The teams of universities and small and medium-sized enterprises in the project will have access to this unique library of chemicals and are expected to add another 200,000 compounds. The screening center will build on industry’s expertise in high-throughput screening—a testing method in which robots test hundreds of thousands of unique chemicals for biological activity.

The European Lead Factory will provide to public partners an industry-like discovery platform to translate cutting-edge academic research into high-quality candidate drug molecules on a scale and speed that was not possible previously. Such candidates will be directly introduced to the drug development process for further refinement or will serve as research tools to improve understanding of disease mechanisms.

The joint screening center will give academic teams a unique opportunity to work in conditions that meet industry standards, facilitating the translation of their findings into actual treatments for patients,” said Michel Goldman, IMI’s executive director. “This shared facility, together with the joint European Compound Collection, will greatly advance the chances of success in the discovery of new medicines for researchers in Europe.

The total budget for the project amounts to $222 million: up to $105 million will be provided by the European Commission’s seventh Framework Program for Research (FP7) and up to $117 million will be provided in in-kind contributions by the participating companies that are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.